Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).

Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M.

Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31864-5. doi: 10.1016/j.ygyno.2019.12.034. [Epub ahead of print] Review.

PMID:
31924334
2.

Sunset, or dawn of a new age for ovarian cancer vaccine therapy?

Hinchcliff E, Jazaeri AA.

Gynecol Oncol. 2019 Dec;155(3):387-388. doi: 10.1016/j.ygyno.2019.11.011. No abstract available.

PMID:
31812214
3.

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.

Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C.

Cancer Immunol Immunother. 2019 Nov;68(11):1747-1757. doi: 10.1007/s00262-019-02402-z. Epub 2019 Oct 10.

PMID:
31602489
4.

B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature.

Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA.

Gynecol Oncol Rep. 2019 Aug 12;29:94-97. doi: 10.1016/j.gore.2019.08.003. eCollection 2019 Aug.

5.

Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.

Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M.

Cancer Res. 2019 Sep 15;79(18):4599-4611. doi: 10.1158/0008-5472.CAN-19-0215. Epub 2019 Jul 29.

6.

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.

Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.

J Immunother Cancer. 2019 May 3;7(1):118. doi: 10.1186/s40425-019-0604-2.

7.

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.

Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y.

J Immunother Cancer. 2019 Feb 6;7(1):31. doi: 10.1186/s40425-019-0502-7.

8.

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.

Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA.

Front Immunol. 2018 Sep 19;9:2102. doi: 10.3389/fimmu.2018.02102. eCollection 2018.

9.

Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes.

Johnson C, Jazaeri AA.

Clin Ther. 2018 Mar;40(3):389-394. doi: 10.1016/j.clinthera.2018.02.011. Epub 2018 Mar 5.

PMID:
29519715
10.

Immunotherapy in ovarian cancer: where are we now, and where are we going?

Jazaeri AA.

Clin Adv Hematol Oncol. 2017 Nov;15(11):851-853. No abstract available.

PMID:
29200418
11.

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL.

J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.

PMID:
28901560
12.

Immunotherapy in Gynecologic Cancers: Are We There Yet?

Pakish JB, Jazaeri AA.

Curr Treat Options Oncol. 2017 Aug 24;18(10):59. doi: 10.1007/s11864-017-0504-y. Review.

13.

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J.

Front Immunol. 2017 Jun 16;8:689. doi: 10.3389/fimmu.2017.00689. eCollection 2017.

14.

Immunotherapy for gynecological cancers: opportunities abound.

Nelson BH, Jazaeri AA.

Gynecol Oncol. 2017 Jun;145(3):411-412. doi: 10.1016/j.ygyno.2017.05.003. No abstract available.

PMID:
28552394
15.

Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation.

Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A.

Mol Cancer Res. 2017 Sep;15(9):1197-1205. doi: 10.1158/1541-7786.MCR-17-0095. Epub 2017 May 26.

16.

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.

Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC.

Oncotarget. 2017 Feb 28;8(9):16099. doi: 10.18632/oncotarget.15755. No abstract available.

17.

Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA.

Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May.

18.

Potential immunotherapy targets in recurrent cervical cancer.

Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA.

Gynecol Oncol. 2017 Jun;145(3):462-468. doi: 10.1016/j.ygyno.2017.02.027. Epub 2017 Feb 21.

PMID:
28233576
19.

Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.

Ring KL, Pakish J, Jazaeri AA.

Cancer J. 2016 Mar-Apr;22(2):101-7. doi: 10.1097/PPO.0000000000000179. Review.

PMID:
27111905
20.

Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Zamarin D, Jazaeri AA.

Gynecol Oncol. 2016 Apr;141(1):86-94. doi: 10.1016/j.ygyno.2015.12.030. Review.

21.

Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia.

Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, Jazaeri AA, Huang Z, Murphy SK, Mythreye K.

Neoplasia. 2015 Nov;17(11):826-38. doi: 10.1016/j.neo.2015.11.003.

22.

Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.

Pires ES, D'Souza RS, Needham MA, Herr AK, Jazaeri AA, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC.

Oncotarget. 2015 Oct 6;6(30):30194-211. doi: 10.18632/oncotarget.4734. Erratum in: Oncotarget. 2017 Feb 28;8(9):16099.

23.

SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization.

Qiao Y, Quinlan AR, Jazaeri AA, Verhaak RG, Wheeler DA, Marth GT.

Genome Biol. 2014 Aug 26;15(8):443. doi: 10.1186/s13059-014-0443-x.

24.

Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era.

Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA, Cantrell LA, Duska LR.

Gynecol Oncol Case Rep. 2013 Feb 11;5:6-9. doi: 10.1016/j.gynor.2013.02.002. eCollection 2013.

25.

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A.

Mol Cancer Ther. 2013 Oct;12(10):1958-67. doi: 10.1158/1535-7163.MCT-12-1028. Epub 2013 Aug 12.

26.

Frailty: an outcome predictor for elderly gynecologic oncology patients.

Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA.

Gynecol Oncol. 2012 Jul;126(1):20-4. doi: 10.1016/j.ygyno.2012.04.019. Epub 2012 Apr 19.

PMID:
22522190
27.

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A.

Neoplasia. 2011 Oct;13(10):899-911.

28.

A nomogram for estimating the probability of ovarian cancer.

Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ.

Gynecol Oncol. 2011 Apr;121(1):2-7. doi: 10.1016/j.ygyno.2010.12.365. Epub 2011 Jan 26.

PMID:
21269667
29.

Appendiceal pathology at the time of oophorectomy for ovarian neoplasms.

Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA.

Obstet Gynecol. 2010 Dec;116(6):1348-53. doi: 10.1097/AOG.0b013e3181fae628.

PMID:
21099601
30.

Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.

Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A.

Gynecol Oncol. 2010 Aug 1;118(2):189-95. doi: 10.1016/j.ygyno.2010.04.007. Epub 2010 May 11.

PMID:
20462630
31.

Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.

Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA.

Int J Gynecol Cancer. 2010 Jan;20(1):120-5. doi: 10.1111/IGC.0b013e3181c7fe53.

PMID:
20130512
32.

CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis.

Terai K, Abbas T, Jazaeri AA, Dutta A.

Mol Cell. 2010 Jan 15;37(1):143-9. doi: 10.1016/j.molcel.2009.12.018.

33.

The promise of antiangiogenic therapy for ovarian cancer.

Jazaeri AA, Slack-Davis JK.

Cancer Biol Ther. 2009 Dec;8(23):2273-4. Epub 2009 Dec 25. No abstract available.

PMID:
19907207
34.

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report.

Greene DP, Ferriss JS, Jazaeri AA.

Cancer Chemother Pharmacol. 2010 Jul;66(2):265-7. doi: 10.1007/s00280-009-1159-6. Epub 2009 Oct 21.

PMID:
19844714
35.

Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.

Jazaeri AA.

Mol Oncol. 2009 Apr;3(2):151-6. doi: 10.1016/j.molonc.2009.01.001. Epub 2009 Feb 7. Review.

36.

Utilization of a uniform grading system for interpreting serous ovarian cancer.

Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, Jazaeri AA.

Am J Obstet Gynecol. 2008 Aug;199(2):189.e1-6. doi: 10.1016/j.ajog.2008.04.031. Epub 2008 May 23.

PMID:
18501326
37.

A cost comparison of two strategies for treating stage IB2 cervical cancer.

Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA.

Int J Gynecol Cancer. 2008 Mar-Apr;18(2):274-8. doi: 10.1111/j.1525-1438.2007.01007.x.

PMID:
18334009
38.

Cyclooxygenase-2 in cervical neoplasia: a review.

Young JL, Jazaeri AA, Darus CJ, Modesitt SC.

Gynecol Oncol. 2008 Apr;109(1):140-5. doi: 10.1016/j.ygyno.2008.01.008. Epub 2008 Feb 13. Review.

PMID:
18275990
39.

Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma.

Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, Jazaeri AA.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):730-5. Epub 2007 Oct 19.

PMID:
17949426
40.

A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma.

Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA.

Gynecol Oncol. 2008 Jan;108(1):77-83. Epub 2007 Oct 22.

PMID:
17936341
41.

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.

Modesitt SC, Jazaeri AA.

Expert Opin Pharmacother. 2007 Oct;8(14):2293-305. Review.

PMID:
17927484
42.

Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA.

Am J Obstet Gynecol. 2007 Aug;197(2):199.e1-4; discussion 199.e4-5.

PMID:
17689649
43.

Cervical adenocarcinoma in situ: the predictive value of conization margin status.

Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC.

Am J Obstet Gynecol. 2007 Aug;197(2):195.e1-7; discussion 195.e7-8.

PMID:
17689647
44.

Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.

Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT Jr.

Am J Obstet Gynecol. 2006 Aug;195(2):568-74; discussion 574-6.

PMID:
16890558
45.

Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.

Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, Jazaeri AA.

Am J Obstet Gynecol. 2006 Apr;194(4):1119-26; discussion 1126-8.

PMID:
16580307
46.

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.

Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.

Clin Cancer Res. 2005 Sep 1;11(17):6300-10.

47.

BRCA1-mediated repression of select X chromosome genes.

Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC.

J Transl Med. 2004 Sep 21;2(1):32.

48.

Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.

Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ.

Clin Cancer Res. 2003 Oct 15;9(13):4811-8.

49.

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET.

Mol Carcinog. 2003 Feb;36(2):53-9.

PMID:
12557260
50.

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET.

J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000.

PMID:
12096084

Supplemental Content

Loading ...
Support Center